The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $52.40

Today's change+0.83 +1.61%
Updated September 4 3:41 PM EDT. Delayed by at least 15 minutes.
 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $52.40

Today's change+0.83 +1.61%
Updated September 4 3:41 PM EDT. Delayed by at least 15 minutes.

Isis Pharmaceuticals Inc Hits New 20-day High

Isis Pharmaceuticals Inc is up sharply today, rallying (U.S.)$0.83 or 1.61% to (U.S.)$52.40 and setting a new 20-day high. Over the last five days, shares have gained 1.67%, but are down 15.13% for the last year to date. Shares have outperformed the S&P 500 by 37.68% during the last year.

Key company metrics

  • Open(U.S.) $50.87
  • Previous close(U.S.) $51.57
  • High(U.S.) $52.40
  • Low(U.S.) $50.25
  • Bid / Ask(U.S.) $52.39 / (U.S.) $52.41
  • YTD % change-15.13%
  • Volume903,202
  • Average volume (10-day)2,045,002
  • Average volume (1-month)1,841,243
  • Average volume (3-month)2,208,964
  • 52-week range(U.S.) $35.26 to (U.S.) $77.80
  • Beta1.63
  • Trailing P/E286.56×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.18
Updated September 4 3:41 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.82%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue120638544
Total other revenue--------
Total revenue120638544
Gross profit52-217-17
Total cost of revenue68646861
Total operating expense76728366
Selling / general / administrative8774
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----8--
Other operating expenses, total--------
Operating income45-92-21
Interest income (expense), net non-operating-9-9-7-5
Gain (loss) on sale of assets--------
Other--------
Income before tax36-1816-25
Income after tax36-1731-27
Income tax, total1-1-151
Net income36-1731-27
Total adjustments to net income--------
Net income before extra. items36-1731-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items36-1731-27
Inc. avail. to common incl. extra. items36-1731-27
Diluted net income37-1731-27
Dilution adjustment1------
Diluted weighted average shares128119118118
Diluted EPS excluding extraordinary itemsvalue per share0.29-0.140.26-0.23
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.29-0.140.31-0.23